Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
|Videos|November 28, 2014
Pharmacy Times Asks a Burmans Pharmacist: What Are Your Wellness Initiatives?
Vince Canzanese, RPh, director of compounding at Burmans Pharmacy in Brookhaven, Pennsylvania, discusses the independent pharmacy's wellness initiatives.
Advertisement
Vince Canzanese, RPh, director of compounding at
“At Burmans, we’ve championed a lot of health initiatives,” he says. “One of our biggest ones is weight management or diabetes management for patients. That centers around compliance and health attitudes.”
Advertisement
Related to this article
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
2
Flu Vaccination Linked to Fewer Severe Outcomes in Older Adults, Fewer ED Visits in Children
3
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
4
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
5